Slikkerveer A, Noach L A, Tytgat G N, Van der Voet G B, De Wolff F A
Toxicology Laboratory, Leiden University Medical Centre, The Netherlands.
Analyst. 1998 Jan;123(1):91-2. doi: 10.1039/a704945e.
Two groups of 12 human volunteers, who had been treated with colloidal bismuth subcitrate, because of Helicobacter pylori-associated gastritis, participated in the study. The patients received a single dose of meso-2,3-dimercaptosuccinic acid (DMSA) or D,L-2,3-dimercaptopropane-1-sulfonic acid (DMPS) at a dose of 30 mg kg-1 in a randomized single blind study. In contrast to DMPS, increasing concentrations of bismuth in blood were observed during the first 4 h after intake of DMSA. In urine, both chelators induced a 50-fold increase in urinary bismuth excretion compared with the control urines. The treatment was well tolerated. The results indicate that both DMSA and DMPS effectively increase the elimination of bismuth in human urine. Consequently, both chelators may be of benefit in the treatment of patients with bismuth intoxication.
两组各12名因幽门螺杆菌相关性胃炎而接受胶体次枸橼酸铋治疗的人类志愿者参与了该研究。在一项随机单盲研究中，患者接受了剂量为30 mg/kg的单剂量内消旋-2,3-二巯基琥珀酸（DMSA）或D,L-2,3-二巯基丙烷-1-磺酸（DMPS）。与DMPS不同，摄入DMSA后的前4小时内，血液中的铋浓度有所升高。在尿液中，与对照尿液相比，两种螯合剂均使尿铋排泄增加了50倍。该治疗耐受性良好。结果表明，DMSA和DMPS均能有效增加人体尿液中铋的排泄。因此，两种螯合剂可能对铋中毒患者的治疗有益。
